Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Aqualane Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,940,397

121 payments

Through program year 2025, Aqualane Clinical Research LLC is reported as receiving $2,940,397 in research payments, across 121 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $1,182,896 81
2024 Research $1,058,364 28
2023 Research $644,223 10
2022 Research $54,914 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $881,508 14 payments
  2. Janssen Research & Development, LLC $562,128 29 payments
  3. Ucb SA $497,336 6 payments
  4. Sage Therapeutics, Inc. $312,047 6 payments
  5. Novartis Pharmaceuticals Corporation $263,497 8 payments
  6. Amgen Inc. $195,280 1 payment
  7. Alnylam Pharmaceuticals Inc. $90,689 24 payments
  8. H. Lundbeck A S $73,086 19 payments
  9. Genzyme Corporation $42,385 9 payments
  10. Pfizer Inc. $18,440 4 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $520,102 22 payments
  2. A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (Ucb0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (Ad), Followed By An Open-Label Extension Period $392,650 2 payments
  3. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $347,146 3 payments
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $269,796 1 payment
  5. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $230,083 3 payments
  6. A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis $195,280 1 payment
  7. Study to Evaluate SAGE-324 in Participants With Essential Tremors $191,915 3 payments
  8. A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed By Extended Treatment With Open-Label Remibrutinib $172,235 3 payments
  9. A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor $120,133 3 payments
  10. A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) $90,689 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record